Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Camrelizumab + apatinib + GP
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Camrelizumab + apatinib + GP is a combination therapy regimen used in oncology, particularly for advanced or metastatic cancers. Camrelizumab is a humanized monoclonal antibody targeting the programmed death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor to enhance T-cell mediated antitumor responses. Apatinib is a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking angiogenesis and tumor blood supply. The "GP" component refers to gemcitabine plus cisplatin chemotherapy, which are cytotoxic agents commonly used in various solid tumors including nasopharyngeal carcinoma and other advanced malignancies. This combination leverages immunotherapy, antiangiogenic therapy, and cytotoxic chemotherapy for synergistic antitumor effects[1][2][3][4][5].
- Brand names
- Camrelizumab: AiRuiKaApatinib: Aitan
02
Targets
DNADNA polymerase familyPDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on Camrelizumab + apatinib + GP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Camrelizumab + apatinib + GP.